Francesca Iacobellis, Marco Di Serafino, Camilla Russo, Roberto Ronza, Martina Caruso, Giuseppina Dell'Aversano Orabona, Costanza Camillo, Vittorio Sabatino, Dario Grimaldi, Chiara Rinaldo, Luigi Barbuto, Francesco Verde, Giuliana Giacobbe, Maria Laura Schillirò, Enrico Scarano, Luigia Romano
Gadolinium-based contrast agents (GBCAs) have helped to improve the role of magnetic resonance imaging (MRI) for the diagnosis and treatment of diseases. There are currently nine different commercially available gadolinium-based contrast agents (GBCAs) that can be used for body MRI cases, and which are classifiable according to their structures (cyclic or linear) or biodistribution (extracellular-space agents, target/specific-agents, and blood-pool agents). The aim of this review is to illustrate the commercially available MRI contrast agents, their effect on imaging, and adverse reaction on the body, with the goal to lead to their proper selection in different clinical contexts...
April 10, 2024: Journal of Clinical Medicine